myNEO Therapeutics

myNEO evolves into myNEO Therapeutics to reflect its new strategy to develop off-the-shelf cancer vaccine immunotherapeutics

myNEO Therapeutics to focus on building proprietary product pipeline based on a novel class of shared therapeutic cancer targets derived from the dark genome named “camyotopes” Lead product CAMYO-01 incorporates a pool of colorectal cancer-specific camyotopes formulated into an mRNA-based vaccine CAMYO-01 is advancing towards clinical development for the treatment of colorectal cancer 25 October...
Ottergemsesteenweg 439 9000 Ghent Belgium